Abstract
Revolutionary diagnostic kit enables rapid, early detection of Spirocerca lupi parasitic infections in dogs using proprietary biomarker technology, transforming treatment outcomes.
Background
Spirocerca lupi represents one of the most devastating parasitic threats to canine health globally, with endemic presence across Israel, South Africa, Turkey, Greece, India, Brazil, Australia, and throughout Asia. This pathogenic nematode causes severe esophageal and aortic lesions, with 20% of infections progressing to malignant transformation and metastases. The global companion animal healthcare market, valued at $23.16 billion in 2022 and projected to reach $39.21 billion by 2030³, faces significant challenges from parasitic diseases requiring expensive, invasive diagnostic procedures.
Current diagnostic methods rely on endoscopic examination or fecal analysis, typically requiring 6 months post-infection for reliable detection – often too late for effective intervention. The existing diagnostic gap requires preventative treatment protocols using expensive injectable medications administered every 2-3 months, creating substantial ongoing costs for pet owners and veterinary practices.
Key competitors include traditional fecal flotation methods, endoscopic diagnosis. However, these solutions suffer from delayed detection windows, high costs ($200-500 per endoscopic procedure), and requirement for specialized veterinary facilities.
Our Innovation
We are developing a rapid, point-of-care diagnostic kit that enables early-stage detection of Spirocerca lupi infections through identification of a specific biomarker unique to this parasite.
Major Technological Advantages:
- Breakthrough Early Detection: Identifies infections using a validated biomarker that shows 132x higher recognition in infected vs. healthy dogs (p<0.01)
- Scientifically Validated Specificity: Mass spectrometry-confirmed actin peptides show 4-fold higher recognition (p<0.005) with zero cross-reactivity to other nematodes (Toxocara canis, Dirofilaria immitis)
- Point-of-Care Convenience: ELISA-based format enables in-clinic testing, eliminating need for specialized endoscopic procedures
- Cost-Effective Solution: Reduces diagnostic costs compared to current endoscopic methods (estimated $20-50 per test vs. $200-500)
- Proven Clinical Performance: Statistically significant differentiation (p<0.0001) between infected dogs and all control groups including endemic area dogs and other parasitic infections
Market Impact: In endemic regions like Israel where 15-30% of dogs may be exposed, this technology could generate $50-100 million annually in diagnostic testing alone. Global market potential exceeds $500 million considering the 900+ million owned dogs worldwide and expanding veterinary care markets in developing countries. The proven biomarker approach opens additional opportunities for vaccine development using the same actin target.
Technology
The diagnostic platform identified through advanced proteomics and mass spectrometry analysis. The technology leverages a unique biomarker for Spirocerca lupi, which provides species-specific detection capability. The kit employs ELISA-based methodology with purified recombinant antigen, delivering results within hours through standard laboratory protocols adaptable to point-of-care formats.
Scientific Foundation: Comprehensive validation included Western blot analysis, immunoprecipitation, tandem mass spectrometry, and multi-cohort ELISA testing across infected dogs (n=9), laboratory controls (n=7), non-endemic dogs (n=6), and dogs with other parasitic infections (n=4).
Opportunity
The researchers are looking for an industry partner to collaborate and sponsor additional research. The partner will receive an option to license the intellectual property at the end of the R&D phase, positioning them at the forefront of the rapidly expanding point-of-care veterinary diagnostics market with a scientifically validated, patent-ready technology.
Patents
Patent: Pre-filing
Scientific Article: ongoing rd.
